Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting

Executive Summary

• Telo Genomics presented initial clinical data on a novel Minimal Residual Disease (MRD) test for Multiple Myeloma at the 67th ASH Annual Meeting.
• The assay combines enumeration of circulating tumor cells (CTCs) from peripheral blood with 3‑D telomere profiling (TeloView®), achieving a limit of detection of 1 in 10⁷ cells.
• Early results show distinct 3‑D genome profile clusters that correlate with high/low mutation rates, supporting potential prognostic use; larger validation studies are now underway.

Key Details

• Presentation: Poster titled “Novel method of minimal residual disease testing in myeloma: liquid biopsies to enumerate and 3D telomere‑profile circulating tumor cells” presented by Dr. Yulia Shifrin (Laboratory Director).
• Publication: Abstract published in the conference journal Blood; poster available on Telo Genomics website.
• Assay Performance: Limit of detection = 1 myeloma cell per 10 million peripheral blood cells (1 × 10⁻⁷).
• Technology: Integration of CTC enumeration with TeloView® 3‑D telomere profiling platform.
• Biological Insight: Identified distinct clusters of 3‑D genome profiles that align with known high/low mutation rate patterns, offering functional information beyond simple cell counts.
• Clinical Implication: Provides a less invasive alternative to bone‑marrow biopsies for continuous MRD monitoring; may aid in risk stratification and early detection of relapse.
• Regulatory Context: FDA’s Oncologic Drugs Advisory Committee (April 2024) accepted MRD as an endpoint for accelerated approval of MM therapies, underscoring the relevance of MRD testing.
• Market Outlook: Global MRD testing market projected to reach USD 4.1 billion by 2032; addressable market for MM assays estimated at >750,000 tests/year in the U.S.

Notable Quotes

“This method provides functional, biological information about the residual disease cells themselves, offering insights into progression risk beyond cell counts,” – Dr. Sabine Mai, Co‑founder and Interim CEO, Telo Genomics.

All boilerplate, forward‑looking disclaimer, and company background sections have been omitted for brevity.